share_log

君聖泰醫藥-B：董事會會議召開日期通告

HIGHTIDE-B: NOTICE OF DATE OF BOARD MEETING

Hong Kong Stock Exchange ·  Mar 15 04:59
Summary by Moomoo AI
君圣泰医药-B（股份代號：2511）宣佈，將於2024年3月27日（星期三）召開董事會會議，主要目的是審議及批准公司及其附屬公司截至2023年12月31日止年度的經審核全年業績及其發佈。會議將由執行董事兼行政總裁劉利平博士主持，並有其他董事會成員參與，包括執行董事于萌女士、非執行董事朱迅博士、馬立雄先生及江峰先生，以及獨立非執行董事譚擘先生、李靖博士及孔德偉先生。此次會議除了審議全年業績外，還將處理其他事項。
君圣泰医药-B（股份代號：2511）宣佈，將於2024年3月27日（星期三）召開董事會會議，主要目的是審議及批准公司及其附屬公司截至2023年12月31日止年度的經審核全年業績及其發佈。會議將由執行董事兼行政總裁劉利平博士主持，並有其他董事會成員參與，包括執行董事于萌女士、非執行董事朱迅博士、馬立雄先生及江峰先生，以及獨立非執行董事譚擘先生、李靖博士及孔德偉先生。此次會議除了審議全年業績外，還將處理其他事項。
Jun Shing Tai Pharmaceutical-B (Stock Code: 2511) announces that a Board Meeting will be held on Wednesday, March 27, 2024. The primary purpose of which is to review and approve the audited annual results of the Company and its subsidiaries for the year ended December 31, 2023 and their publication. The meeting will be chaired by Dr. Liu Liping, Executive Director and Chief Executive Officer, and will be attended by other Board members, including Ms. Yu Meng, Executive Director, Dr. Zhu Xun, Mr. Ma Li-Hung and Mr. Jiang Feng, as well as Independent Non-Executive Directors Mr. Tan Yin, Dr. Li Jing and Mr. Kung De Wei. In addition to reviewing the annual results, the meeting will deal with other matters.
Jun Shing Tai Pharmaceutical-B (Stock Code: 2511) announces that a Board Meeting will be held on Wednesday, March 27, 2024. The primary purpose of which is to review and approve the audited annual results of the Company and its subsidiaries for the year ended December 31, 2023 and their publication. The meeting will be chaired by Dr. Liu Liping, Executive Director and Chief Executive Officer, and will be attended by other Board members, including Ms. Yu Meng, Executive Director, Dr. Zhu Xun, Mr. Ma Li-Hung and Mr. Jiang Feng, as well as Independent Non-Executive Directors Mr. Tan Yin, Dr. Li Jing and Mr. Kung De Wei. In addition to reviewing the annual results, the meeting will deal with other matters.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more